lurasidone : An N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizophrenia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 213046 |
| CHEMBL ID | 1237021 |
| CHEBI ID | 70735 |
| SCHEMBL ID | 677525 |
| MeSH ID | M0517365 |
| Synonym |
|---|
| CHEMBL1237021 |
| chebi:70735 , |
| PDSP2_001043 |
| lurasidone |
| 367514-87-2 |
| (3ar,4s,7r,7as)-2-((1r,2r)-2-(4-(1,2-benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2h-isoindole-1,3-dione |
| EX-3124 |
| n-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide |
| sm13496 |
| sm-13,496 |
| bdbm85222 |
| cas_441351-20-8 |
| (3ar,4s,7r,7as)-2-{(1r,2r)-2-(4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl}hexahydro-4,7-methano-2h-isoindole-1,3-dione |
| hsdb 8228 |
| 22ic88528t , |
| unii-22ic88528t |
| lurasidone [inn] |
| lurasidone [vandf] |
| lurasidone [who-dd] |
| lurasidone [mi] |
| lurasidonum |
| (3ar,4s,7r,7as)-2-{[(1r,2r)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}hexahydro-1h-4,7-methanoisoindole-1,3(2h)-dione |
| lurasidona |
| S5714 |
| DB08815 |
| SCHEMBL677525 |
| gtpl7461 |
| (3ar,4s,7r,7as)-2-{(1r,2r)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2h-isoindole-1,3-dione |
| PQXKDMSYBGKCJA-CVTJIBDQSA-N |
| AB01566875_01 |
| J-521660 |
| sm 13,496 |
| sm13,496 |
| EX-A504 |
| (1r,2s,6r,7s)-4-{[(1r,2r)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0?,?]decane-3,5-dione |
| Q416992 |
| (1s,2r,6s,7r)-4-[[(1r,2r)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione |
| L0280 |
| AS-35077 |
| HMS3886A20 |
| AMY32530 |
| CCG-269635 |
| NCGC00386382-03 |
| AKOS037643746 |
| sm-13496sm13496 |
| (1r,2s,6r,7s)-4-[[(1r,2r)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione |
| DTXSID40870340 |
| EN300-20605510 |
| (1r,2s,6r,7s)-4-{[(1r,2r)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0,2,6]decane-3,5-dione |
| (3ar,4s,7r,7as)-2-((1r,2r)-2-(4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2h-isoindole-1,3-dione |
| n05ae05 |
| (3ar,4s,7r,7as)-2-(((1r,2r)-2-((4-(1,2-benzothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1h-4,7-methanoisoindole-1,3(2h)-dione |
| ps34 - lurasidone |
| Role | Description |
|---|---|
| adrenergic antagonist | An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. |
| dopaminergic antagonist | A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. |
| serotonergic antagonist | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. |
| second generation antipsychotic | Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 1,2-benzisothiazole | A benzothiazole consisting of a benzene ring fused to an isothiazole. |
| N-arylpiperazine | |
| bridged compound | A polycyclic compound in which two rings have two or more atoms in common. |
| dicarboximide | An imide in which the two acyl substituents on nitrogen are carboacyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 31.6228 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.0067 | 0.0001 | 0.5326 | 10.0000 | AID1517957 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.0017 | 0.0000 | 0.6518 | 10.0000 | AID1517960 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.0020 | 0.0001 | 0.6017 | 10.0000 | AID1668155 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0020 | 0.0000 | 0.3855 | 10.0000 | AID1517959 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 (µMol) | 0.0157 | 0.0005 | 0.4546 | 4.7640 | AID1756814 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.0005 | 0.0003 | 0.3806 | 10.0000 | AID1517962; AID1668156 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346049 | Human alpha2A-adrenoceptor (Adrenoceptors) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. |
| AID1345602 | Rat 5-HT1A receptor (5-Hydroxytryptamine receptors) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. |
| AID1345783 | Rat D2 receptor (Dopamine receptors) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. |
| AID1346919 | Rat 5-HT2A receptor (5-Hydroxytryptamine receptors) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. |
| AID1345291 | Human 5-HT7 receptor (5-Hydroxytryptamine receptors) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. |
| AID1346159 | Human alpha2C-adrenoceptor (Adrenoceptors) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. |
| AID1517959 | Displacement of [3H]-Ketanserin from human 5-HT2A receptor expressed in rat cortex tissue incubated for 30 mins by liquid scintillation counting method | |||
| AID1517962 | Displacement of [3H]-5-CT from human 5HT7 receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method | |||
| AID1756815 | Antagonist activity at human 5-HT7A receptor expressed in HEK cell membranes assessed as reduction in serotonin-induced cAMP accumulation incubated for 20 mins by cAMP functional assay relative to control | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263. |
| AID1668156 | Displacement of [3H]-5-CT from human recombinant 5HT7b receptor measured after 2 hrs | |||
| AID1517957 | Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in CHO-K1 cell membranes incubated for 60 mins by microbeta scintillation counting analysis | |||
| AID1756814 | Antagonist activity at human 5-HT7A receptor expressed in HEK cell membranes assessed as reduction in serotonin-induced cAMP accumulation incubated for 20 mins by cAMP functional assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263. |
| AID1668154 | Displacement of [3H]8-OH-DPAT from 5HT1A receptor in rat hippocampus measured after 30 mins | |||
| AID1668153 | Displacement of [3H]-spiperone from D2 receptor in rat striatum measured after 10 mins | |||
| AID1739155 | Plasma protein binding in rat at 2 to 10 uM after 30 mins by LC-MS/MS analysis | 2020 | European journal of medicinal chemistry, Aug-01, Volume: 199 | Privileged scaffold-based design to identify a novel drug-like 5-HT |
| AID1517960 | Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method | |||
| AID1668155 | Displacement of [3H]-ketanserin from 5HT2A receptor in rat cortex measured after 30 mins | |||
| AID1411901 | Drug absorption in po dosed human | 2018 | MedChemComm, May-01, Volume: 9, Issue:5 | Schizophrenia: synthetic strategies and recent advances in drug design. |
| AID1411900 | Receptor occupancy at D2 receptor (unknown origin) | 2018 | MedChemComm, May-01, Volume: 9, Issue:5 | Schizophrenia: synthetic strategies and recent advances in drug design. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (102.40) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||